JO
IMMX icon

John Overdeck’s Immix Biopharma IMMX Stock Holding History

John Overdeck’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$414K Buy
+40,181
New +$373K ﹤0.01% 4299
2024
Q2 		– Sell
-22,862
Closed -$70.2K – 3168
2024
Q1 		$70.2K Buy
+22,862
New +$88.5K ﹤0.01% 2861

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

John Overdeck's IMMX Position: Q2 2026 in Review

John Overdeck opened a new position in Immix Biopharma (IMMX) in Q2 2026: 40,181 shares worth $414K. The stake represents ﹤0.01% of the portfolio and ranks #4299 among its holdings. This is a return to the name: John Overdeck previously reported a position in IMMX as recently as Q1 2024.

John Overdeck first reported a position in IMMX in Q1 2024 and has held it in 2 quarters since. 108 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • John Overdeck held 40,181 shares of Immix Biopharma worth $414K as of Q2 2026.
  • Immix Biopharma was a new John Overdeck position in Q2 2026.
  • Immix Biopharma made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4299 holding.
  • John Overdeck first reported a position in Immix Biopharma in Q1 2024 and has held it in 2 quarters since.
  • 108 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.